Opinion

Video

Reducing Treatment Burden in IBD with At-Home Therapy Options

Jean-Frederic Colombel, MD, offers insights into subcutaneous infliximab-dyyb injection, detailing its administration and approved indications for ulcerative colitis and Crohn's disease.

  1. The FDA has now approved a subcutaneous infliximab injection for IBD. Can you provide an overview of subcutaneous infliximab-dyyb injection? What is the significance of this approval?
    1. How could this impact patients with UC and CD?
  2. What are the indications for subcutaneous infliximab-dyyb injection?
    1. When and how can this therapy be started?
Related Videos
Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Brian Lee, MD | Credit: AASLD
Transformations in Aortic Disease Management with Mehrdad Ghoreishi, MD | Image Credit: Baptist Health South Florida
Importance of Birch Triterpene Findings for Epidermolysis Bullosa, with Anna Bruckner, MD
Phase 3 Findings on Birch Triterpenes for Epidermolysis Bullosa, with Anna Bruckner, MD
© 2025 MJH Life Sciences

All rights reserved.